BCTX BRIACELL THERAPEUTICS CORP US FDA Inspections 8-K Filing 2023 - FDA Approval for Bria-IMTTM Study Design in Breast Cancer BriaCell Therapeutics Corp. received FDA approval for its registration study design for Bria-IMTTM in combination with a checkpoint inhibitor in advanced metastatic breast cancer.Get access to all SEC 8-K filings of the BRIACELL THERAPEUTICS CORP